Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker’s $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.
The offer for Spark shares now runs to Oct. 1, Roche said.
Around 24.1% of Spark’s outstanding shares had been tendered as of the end of August.
“The offer was extended to provide additional time for the U.S. Federal Trade Commission (the ‘FTC’) and the UK Competition and Markets Authority (the ‘CMA’) to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC and the CMA,” a statement said.
By Michael Shields
Source: Reuters
Covid-19 originated in China, which is where the clear majority of APIs for drugs are manufactured; China’s lockdown had a knock-on effect on its neighbour India, which relies on those […]
The continued prosperity of a biopharma company is dependent on its ability to keep churning out breakthrough new drugs and turning them into commercial successes backed by a growing body […]
Clinical trial enrollment has dropped massively across the world with endocrine and cardiovascular tests being the hardest hit. This is according to a new breakdown from Medidata (PDF), now owned […]
